Article info

other Versions

PDF

Extended report
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Authors

  1. Correspondence to Dr Ryan DeMasi; Pfizer Inc, 235 E 42nd St, New York, NY 10017, USA; Ryan.DeMasi{at}pfizer.com
View Full Text

Citation

Cohen SB, Tanaka Y, Mariette X, et al
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Publication history

  • Received 2 September 2016
  • Revised 8 December 2016
  • Accepted 26 December 2016
  • Published online 31 January 2017.

Article Versions

  • Lay summary

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.